Work

High cellular plasticity state of medulloblastoma local recurrence and distant dissemination

Year: 2025
Type: article
Abstract: Medulloblastoma (MB), a heterogeneous pediatric brain tumor, poses challenges in the treatment of tumor recurrence and dissemination. To characterize cellular diversity and genetic features, we comprehensively analyzed single-cell/nucleus RNA sequencing (sc/snRNA-seq), single-nucleus assay for transposase-accessible chromatin sequencing (snATAC-seq), and spatial transcriptomics profiles and identified distinct cellular populations in SHH (sonic hedgehog) and Group_3 subgroups, with varying proportions in local recurrence or dissemination. Local recurrence showed higher cycling tumor cell enrichment, whereas disseminated lesions had a relatively notable presence of differentiated subsets. Chromosomal alteration evaluation revealed distinct genetic subclones during MB progression, such as chr7q gain and chr11 loss in Group_3 disseminations. A subpopulation termed “high cellular plasticity (HCP)” emerged during MB progression and was associated with increased dividing potential and chromatin accessibility, contributing to recurrence. Inhibiting HCP-associated markers, like protein tyrosine phosphatase receptor type Z1 ( PTPRZ1 ), efficiently suppressed MB progression in preclinical models. These findings address critical gaps in understanding the cellular diversity, chromosomal alterations, and biological dynamics of recurrent MB, offering potential therapeutic insights. • Multiomics reveals distinct cellular and genetic events associated with MB recurrence • MB cells with high cellular plasticity (HCP) state contribute to tumor progression • Targeting MB HCP cells improved the outcomes Liu et al. demonstrates that PTPRZ1 is crucial for maintaining the high cellular plasticity (HCP) state during Group_3 medulloblastoma recurrence. Targeting this subpopulation of tumor cells with HCP state effectively mitigates medulloblastoma progression offers a potential treatment for this aggressive disease.
Language: English
Subfield: Oncology
Field: Medicine
Open Access status: gold
Estimated APC paid: $5,620
OpenAlex ID: W4406325174
FWCI: 1.646
Cites: 55
Cited by: 5
Related to: 10